This report is the first in PharmaBoardroom’s InFocus: China Biotech Catalysts series, profiling the companies and leaders shaping the next wave of global biotech innovation. PharmaBoardroom has been at the forefront of China’s biopharma boom for almost 20 years, speaking to founders, pharmas and VCs on the ground and doing more than almost any other Western media platform to bring their insights to a global industry audience.
China’s biotechnology sector has moved from imitation to innovation at remarkable speed. What began with regulatory reforms in 2015 has evolved into a structural shift in global drug development, powered by returning scientific talent, efficient clinical infrastructure, and deep capital markets.
The scale of progress is striking. China now accounts for over 28 percent of the global drug development pipeline, while 18 percent of global licensing deals this year have involved Chinese assets, representing one-third of total deal value. At the same time, the country has become one of the most efficient clinical development environments in the world, with trial costs 40 to 60 percent lower than in the West, supported by an extensive hospital network and vast patient base.
Global pharmaceutical companies are responding in kind. Facing patent expiries and R&D bottlenecks, Pfizer, AstraZeneca, Lilly, Sanofi, and Novartis have all struck billion-dollar partnerships with Chinese firms in recent years. That this surge in collaboration continues despite heightened geopolitical uncertainty underscores the growing pull of China’s scientific and operational capabilities.
After years of fierce competition and consolidation, a new generation of Chinese biotechs has emerged with globally competitive science and platform-based business models. Rather than chasing single molecules, they are building discovery and delivery technologies that can support both internal pipelines and global partnerships.
This edition of InFocus: China Biotech Catalysts profiles three stand-out companies from this wave: Argo Biopharmaceuticals, Duality Biologics, and Harbour BioMed. Each highlights a different dimension of China’s biotech maturity – from RNA therapeutics to antibody-drug conjugates to fully human antibody platforms.
Argo Biopharmaceuticals has positioned itself at the frontier of RNA therapeutics, often described as the fourth pillar of modern medicine alongside small molecules, antibodies, and cell and gene therapies. Its recent partnership with Novartis reflects both the sophistication of its platform and the growing confidence international players now place in Chinese science.
Duality Biologics, led by Dr John Zhu, is advancing China’s presence in oncology through its DualityADC™ platform. Agreements with BioNTech and Mersana Therapeutics have placed it among the leading ADC developers worldwide, part of a segment that has generated over USD 30 billion in deal value since 2020.
Harbour BioMed, founded by Dr Jingsong Wang, built its success on the proprietary HCAb platform that produces fully human antibodies. With collaborators including AbbVie, AstraZeneca, and BeiGene (now BeOne Medicines) and operations across Suzhou, Boston, and Rotterdam, Harbour has become a reference point for Chinese-origin biotechs meeting global standards.
Together, these companies reflect the sophistication, ambition, and global outlook defining China’s current biotech generation. Supported by capital, talent, and regulatory agility, they are no longer catching up but contributing directly to the global flow of new medicines. China’s biotechs have become indispensable partners in discovery and development, signalling a lasting shift in where the world looks for the next medical breakthrough.
This report is the first in PharmaBoardroom’s InFocus: China Biotech Catalysts series, profiling the companies and leaders shaping the next wave of global biotech innovation. PharmaBoardroom has been at the forefront of China’s biopharma boom for almost 20 years, speaking to founders, pharmas and VCs on the ground and doing more than almost any other Western media platform to bring their insights to a global industry audience.
China’s biotechnology sector has moved from imitation to innovation at remarkable speed. What began with regulatory reforms in 2015 has evolved into a structural shift in global drug development, powered by returning scientific talent, efficient clinical infrastructure, and deep capital markets.
The scale of progress is striking. China now accounts for over 28 percent of the global drug development pipeline, while 18 percent of global licensing deals this year have involved Chinese assets, representing one-third of total deal value. At the same time, the country has become one of the most efficient clinical development environments in the world, with trial costs 40 to 60 percent lower than in the West, supported by an extensive hospital network and vast patient base.
Global pharmaceutical companies are responding in kind. Facing patent expiries and R&D bottlenecks, Pfizer, AstraZeneca, Lilly, Sanofi, and Novartis have all struck billion-dollar partnerships with Chinese firms in recent years. That this surge in collaboration continues despite heightened geopolitical uncertainty underscores the growing pull of China’s scientific and operational capabilities.
After years of fierce competition and consolidation, a new generation of Chinese biotechs has emerged with globally competitive science and platform-based business models. Rather than chasing single molecules, they are building discovery and delivery technologies that can support both internal pipelines and global partnerships.
This edition of InFocus: China Biotech Catalysts profiles three stand-out companies from this wave: Argo Biopharmaceuticals, Duality Biologics, and Harbour BioMed. Each highlights a different dimension of China’s biotech maturity – from RNA therapeutics to antibody-drug conjugates to fully human antibody platforms.
Argo Biopharmaceuticals has positioned itself at the frontier of RNA therapeutics, often described as the fourth pillar of modern medicine alongside small molecules, antibodies, and cell and gene therapies. Its recent partnership with Novartis reflects both the sophistication of its platform and the growing confidence international players now place in Chinese science.
Duality Biologics, led by Dr John Zhu, is advancing China’s presence in oncology through its DualityADC™ platform. Agreements with BioNTech and Mersana Therapeutics have placed it among the leading ADC developers worldwide, part of a segment that has generated over USD 30 billion in deal value since 2020.
Harbour BioMed, founded by Dr Jingsong Wang, built its success on the proprietary HCAb platform that produces fully human antibodies. With collaborators including AbbVie, AstraZeneca, and BeiGene (now BeOne Medicines) and operations across Suzhou, Boston, and Rotterdam, Harbour has become a reference point for Chinese-origin biotechs meeting global standards.
Together, these companies reflect the sophistication, ambition, and global outlook defining China’s current biotech generation. Supported by capital, talent, and regulatory agility, they are no longer catching up but contributing directly to the global flow of new medicines. China’s biotechs have become indispensable partners in discovery and development, signalling a lasting shift in where the world looks for the next medical breakthrough.
In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between a Chinese biotech and a…
See our Cookie Privacy Policy Here
